![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Objective: The aim of the present study was to report on adverse events encountered with robotic-assisted treadmill therapy in children and adolescents with gait disorders.
Methods: Eighty-nine patients who underwent a trial of robotic assisted treadmill therapy in the two participating centres were analysed. Demographic data and safety data of the patients were analysed using descriptive statistics.
Results: In 38 (42.7%) out of 89 patients, adverse events were documented. Most commonly, mild skin erythema at the sites of the cuffs of the device and muscle pain were encountered. In five patients (5.6%), open skin lesions (n = 2), joint pain (n = 2) or tendinopathy (n = 1) limited the continuation of the therapy with the Lokomat. No severe side-effects emerged.
Conclusions: Robotic assisted treadmill therapy is a safe method to enable longer periods of gait therapy in children and adolescents with gait disorders.
| Abbreviations | ||
| AE | = | Adverse events |
| BWSTT | = | Body Weight Supported Treadmill Therapy |
| DGO | = | Driven Gait Orthosis |
| CP | = | Cerebral Palsy |
| GMFM | = | Gross Motor Function Measure |
| GMFCS | = | Gross Motor Function Classification System |
| RATT | = | Robotic-assisted treadmill therapy |
| BoNT | = | Botulinum Neurotoxin. |
| Abbreviations | ||
| AE | = | Adverse events |
| BWSTT | = | Body Weight Supported Treadmill Therapy |
| DGO | = | Driven Gait Orthosis |
| CP | = | Cerebral Palsy |
| GMFM | = | Gross Motor Function Measure |
| GMFCS | = | Gross Motor Function Classification System |
| RATT | = | Robotic-assisted treadmill therapy |
| BoNT | = | Botulinum Neurotoxin. |
Objetivo: El objetivo del presente estudio fue reportar los eventos adversos hallados durante la terapia en banda sin fin asistida por robot en niños y adolescentes con trastornos de la marcha.
Métodos: Se analizaron 89 pacientes que participaron en un estudio de terapia en banda sin fin asisitida por robot en los dos centros participantes. La información demográfica y de seguridad de los pacientes fue analizada utilizando estadística descriptiva.
Resultados: En 38 (42.7%) de los 89 pacientes, se reportaron eventos adversos. Los eventos reportados más frecuentemente fueron eritema en el sitio de aplicación de los brazaletes y dolor muscular. En cinco pacientes (5.6%), lesiones abiertas en la piel (n = 2), dolor articular (n = 2) ó tendinopatía (n = 1) limitaron la continuación de la terapia con Lokomat. No aparecieron efetos colaterales severos.
Conclusiones: La terapia en banda sin fin asistida por robot es un método seguro que permite periodos más prolongados de terapia de la marcha en niños y adolescentes con trastornos de la marcha.